FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386083912> ?p ?o ?g. }

• W4386083912 abstract "Immune checkpoint inhibitor (ICI) therapy has demonstrated substantial benefits for certain patients. We try to evaluate the merits and demerits of each immunotherapy to aid clinical treatment.We conducted a comprehensive search of the PubMed, Embase, and Cochrane databases for randomized clinical trials published as of June 10, 2023. Our study included published clinical trials of ICI monotherapy or combination therapy, along with data on treatment-related adverse events (TRAE). Data regarding survival efficacy and adverse events of each randomized controlled trial (RCT) were collected. The Bayesian random effects model was utilized for the network meta-analysis (NMA).This study incorporated 19 RCTs, involving 5900 patients. Among 14 treatment regimens, Pembrolizumab combined with chemotherapy emerged as the most promising primary treatment for overall survival (OS) and objective response rate (ORR). Toripalimab combined with chemotherapy exhibited the highest likelihood of becoming the primary treatment for extending progression-free survival (PFS). Durvalumab showed the lowest probability of adverse events, suggesting a safer profile compared with other drugs. Camrelizumab combined with chemotherapy demonstrated a heightened risk of adverse events. Dual ICI Nivolumab/Ipilimumab surpassed Durvalumab/Tremelimumab in terms of ORR and adverse events. The standard of care (SOC) regimen did not exhibit strong performance across the four outcome indicators.Our analysis suggests that the integration of chemotherapy agents with ICIs enhances its efficacy as a first-line treatment for patients with advanced head and neck cancer (HNC).1 Laryngoscope, 2023." @default.
• W4386083912 created "2023-08-24" @default.
• W4386083912 creator A5008118059 @default.
• W4386083912 creator A5012485094 @default.
• W4386083912 creator A5027835055 @default.
• W4386083912 creator A5036071138 @default.
• W4386083912 creator A5068937883 @default.
• W4386083912 creator A5069576667 @default.
• W4386083912 date "2023-08-23" @default.
• W4386083912 modified "2023-09-23" @default.
• W4386083912 title "Immune Checkpoint Inhibitors Serve as the First‐Line Treatment for Advanced Head and Neck Cancer" @default.
• W4386083912 cites W1617328014 @default.
• W4386083912 cites W1979423827 @default.
• W4386083912 cites W1992447918 @default.
• W4386083912 cites W2003643844 @default.
• W4386083912 cites W2098923148 @default.
• W4386083912 cites W2100327051 @default.
• W4386083912 cites W2123609095 @default.
• W4386083912 cites W2150529573 @default.
• W4386083912 cites W2164777277 @default.
• W4386083912 cites W2171524637 @default.
• W4386083912 cites W2529484692 @default.
• W4386083912 cites W2791483720 @default.
• W4386083912 cites W2890100090 @default.
• W4386083912 cites W2898717093 @default.
• W4386083912 cites W2901385432 @default.
• W4386083912 cites W2903493423 @default.
• W4386083912 cites W2904060958 @default.
• W4386083912 cites W2986633517 @default.
• W4386083912 cites W2997271239 @default.
• W4386083912 cites W3010839046 @default.
• W4386083912 cites W3015755028 @default.
• W4386083912 cites W3016997444 @default.
• W4386083912 cites W3029965317 @default.
• W4386083912 cites W3080889076 @default.
• W4386083912 cites W3080936926 @default.
• W4386083912 cites W3147500389 @default.
• W4386083912 cites W3177205810 @default.
• W4386083912 cites W3190270536 @default.
• W4386083912 cites W3196164298 @default.
• W4386083912 cites W3204336527 @default.
• W4386083912 cites W4210406669 @default.
• W4386083912 cites W4221131942 @default.
• W4386083912 cites W4306921237 @default.
• W4386083912 cites W4307454808 @default.
• W4386083912 cites W4311654154 @default.
• W4386083912 cites W4312019951 @default.
• W4386083912 cites W4362657687 @default.
• W4386083912 cites W4366084359 @default.
• W4386083912 doi "https://doi.org/10.1002/lary.30971" @default.
• W4386083912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37610169" @default.
• W4386083912 hasPublicationYear "2023" @default.
• W4386083912 type Work @default.
• W4386083912 citedByCount "0" @default.
• W4386083912 crossrefType "journal-article" @default.
• W4386083912 hasAuthorship W4386083912A5008118059 @default.
• W4386083912 hasAuthorship W4386083912A5012485094 @default.
• W4386083912 hasAuthorship W4386083912A5027835055 @default.
• W4386083912 hasAuthorship W4386083912A5036071138 @default.
• W4386083912 hasAuthorship W4386083912A5068937883 @default.
• W4386083912 hasAuthorship W4386083912A5069576667 @default.
• W4386083912 hasBestOaLocation W43860839121 @default.
• W4386083912 hasConcept C121608353 @default.
• W4386083912 hasConcept C126322002 @default.
• W4386083912 hasConcept C143998085 @default.
• W4386083912 hasConcept C168563851 @default.
• W4386083912 hasConcept C197934379 @default.
• W4386083912 hasConcept C2775949291 @default.
• W4386083912 hasConcept C2776530083 @default.
• W4386083912 hasConcept C2777701055 @default.
• W4386083912 hasConcept C2777742743 @default.
• W4386083912 hasConcept C2779998722 @default.
• W4386083912 hasConcept C2780030458 @default.
• W4386083912 hasConcept C2780057760 @default.
• W4386083912 hasConcept C2781413609 @default.
• W4386083912 hasConcept C2781433595 @default.
• W4386083912 hasConcept C526805850 @default.
• W4386083912 hasConcept C535046627 @default.
• W4386083912 hasConcept C71924100 @default.
• W4386083912 hasConceptScore W4386083912C121608353 @default.
• W4386083912 hasConceptScore W4386083912C126322002 @default.
• W4386083912 hasConceptScore W4386083912C143998085 @default.
• W4386083912 hasConceptScore W4386083912C168563851 @default.
• W4386083912 hasConceptScore W4386083912C197934379 @default.
• W4386083912 hasConceptScore W4386083912C2775949291 @default.
• W4386083912 hasConceptScore W4386083912C2776530083 @default.
• W4386083912 hasConceptScore W4386083912C2777701055 @default.
• W4386083912 hasConceptScore W4386083912C2777742743 @default.
• W4386083912 hasConceptScore W4386083912C2779998722 @default.
• W4386083912 hasConceptScore W4386083912C2780030458 @default.
• W4386083912 hasConceptScore W4386083912C2780057760 @default.
• W4386083912 hasConceptScore W4386083912C2781413609 @default.
• W4386083912 hasConceptScore W4386083912C2781433595 @default.
• W4386083912 hasConceptScore W4386083912C526805850 @default.
• W4386083912 hasConceptScore W4386083912C535046627 @default.
• W4386083912 hasConceptScore W4386083912C71924100 @default.
• W4386083912 hasFunder F4320321001 @default.
• W4386083912 hasLocation W43860839121 @default.
• W4386083912 hasLocation W43860839122 @default.
• W4386083912 hasOpenAccess W4386083912 @default.

• next